• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • DeviceTalks Weekly
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
    • DeviceTalks
  • Coronavirus: Live updates

Pulmatrix Inc.

Pulmatrix completes $40M offering, updates product pipeline timetable

March 4, 2021 By Sean Whooley

Pulmatrix (NSDQ:PULM) announced today that it completed an offering with gross proceeds of approximately $40 million. Lexington, Mass.-based Pulmatrix said in a news release that it completed the registered direct offering to extend the company’s cash runway. Now, the company has additional financing to help fully fund data readouts across its development pipeline, which includes […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup, Pharmaceutical, Research & Development Tagged With: Pulmatrix Inc.

Pulmatrix doses first patient in Pulmazole trial

September 19, 2019 By Sean Whooley

Pulmatrix (NSDQ:PULM) said yesterday that it dosed the first patient in its Phase II trial of Pulmazole for the treatment of allergic bronchopulmonary aspergillosis asthmatics. The 64-patient study is a randomized, double-blinded, placebo-controlled trial to evaluate the safety and efficacy of three dose levels of the anti-fungal drug itraconazole formulation Pulmazole. The multi-center, four-arm trial will […]

Filed Under: Clinical Trials, Respiratory Tagged With: Pulmatrix Inc.

‘Berkmorgazon’ health play Haven COO Stoddard steps away | Personnel Moves – May 17, 2019

May 17, 2019 By Fink Densford

Healthcare joint venture Haven, started by Amazon (NSDQ:AMZN), Berkshire Hathaway and J.P. Morgan, has lost its COO Jack Stoddard at just nine months post-hiring, according to a CNBC report. The former digital health general manager for Comcast told the news channel that he is departing the healthcare play due to personal reasons, including the distance between […]

Filed Under: Business/Financial News Tagged With: Amazon, avitamedical, Berkshire Hathaway, Boston Scientific, Cantel Medical Corp., Fresenius, gerresheimer, haven, JP Morgan Chase, oculartherapeutix, proteor, Pulmatrix Inc.

Pulmatrix, Cipla Technologies ink deal for inhaled anti-fungal

April 16, 2019 By Fink Densford

Pulmatrix (NSDQ:PULM) said yesterday that it inked a deal with Cipla to co-develop and commercialize an inhaled iSperse formulation of the anti-fungal drug itraconazole, intended for treating allergic bronchopulmonary aspergillosis in asthma patients. Lexington, Mass.-based Pulmatrix said that it in the deal, Cipla’s Cipla Tech subsidiary will make an upfront payment of $22 million to Pulmatrix […]

Filed Under: Business/Financial News, Drug-Device Combinations, Pharmaceutical, Respiratory Tagged With: Pulmatrix Inc.

Pulmatrix prices $14m offering

April 4, 2019 By Fink Densford

Pulmatrix (NSDQ:PULM) yesterday priced an upcoming offering looking to raise approximately $14.4 million. The Lexington, Mass.-based company said that it plans to float approximately 10.7 million units at a price of $1.35 per unit. Each unit in the offering is comprised of one share of common stock and one warrant to purchase a single share of […]

Filed Under: Business/Financial News, Wall Street Beat Tagged With: Pulmatrix Inc.

Pulmatrix announces 1-for-10 reverse split, $1m offering

February 8, 2019 By Fink Densford

Pulmatrix (NSDQ:PULM) this week announced both a 1-for-10 reverse split of its stock and the closing of an offering which brought in approximately $905,000. On Tuesday, the Lexington, Mass.-based company said that it initiated a 1-for-10 reverse split of its common stock, putting a single share in the hands of each shareholder for each 10 shares they […]

Filed Under: Business/Financial News, Featured, Wall Street Beat Tagged With: Pulmatrix Inc.

Pulmatrix wins FDA nod for PhII trial of inhaled anti-fungal therapy

February 7, 2019 By Sarah Faulkner

Pulmatrix (NSDQ:PULM) said today that the FDA approved a Phase II trial of the company’s inhaled formulation of the anti-fungal drug itraconazole for the treatment of allergic bronchopulmonary aspergillosis in people with asthma. The Lexington, Mass.-based company plans to kick off the trial in the first half of 2019, with top-line data expected in the second […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pharmaceutical, Regulatory/Compliance, Respiratory, Wall Street Beat Tagged With: Pulmatrix Inc.

Pulmatrix raises $3m in offering

November 30, 2018 By Sarah Faulkner

Pulmatrix (NSDQ:PULM) said this week that it inked a deal with an institutional investor to sell 9,375,000 shares of common stock at 32¢ apiece. The Lexington, Mass.-based company expects to reel in $3 million in total gross proceeds from the offering. Get the full story at our sister site, Drug Delivery Business News.

Filed Under: Clinical Trials, Drug-Device Combinations, Funding Roundup, Pharmaceutical, Respiratory, Wall Street Beat Tagged With: Pulmatrix Inc.

Pulmatrix touts data from first-in-human trial of inhaled anti-fungal therapy

July 17, 2018 By Sarah Faulkner

Pulmatrix (NSDQ:PULM) said today that all dosing and follow-up visits have finished for its first-in-human study of an inhaled formulation of itraconazole as a treatment of allergic bronchopulmonary aspergillosis in people with asthma. The inhaled iSperse formulation, called Pulmazole, was well-tolerated, according to the Lexington, Mass.-based company. Pulmatrix plans to launch a Phase II trial of […]

Filed Under: Clinical Trials, Drug-Device Combinations, Pharmaceutical, Wall Street Beat Tagged With: Pulmatrix Inc.

Pulmatrix touts Ph1 data for inhaled COPD therapy

June 13, 2018 By Sarah Faulkner

Pulmatrix (NSDQ:PULM) touted data today from a dose-ranging Phase I trial of its once-daily inhaled therapy designed for people with chronic obstructive pulmonary disease. The company’s product is a reformulation of tiotropium bromide, the active component in Boehringer Ingelheim’s blockbuster drug, Spiriva. Get the full story at our sister site, Drug Delivery Business News.

Filed Under: Clinical Trials, Drug-Device Combinations, Pharmaceutical, Respiratory, Wall Street Beat Tagged With: Pulmatrix Inc.

Pulmatrix prices $15m underwritten public offering

March 29, 2018 By Sarah Faulkner

Pulmatrix (NSDQ:PULM) today priced an underwritten public offering of 23,500,000 units, including one share of common stock, one Series A warrant to buy one share of common stock and one Series B warrant to buy one share of common stock per unit. The Lexington, Mass.-based company also gave underwriters a 30-day option to buy an additional […]

Filed Under: Drug-Device Combinations, Funding Roundup, Pharmaceutical, Research & Development, Respiratory, Wall Street Beat Tagged With: Pulmatrix Inc.

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us

Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS